Clinical trial safety reporting is an integral part of the clinical study process. GCP guidelines give clear requirements regarding the reporting of serious adverse events (SAEs) and abnormalities.
An adverse event can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
